This study is for participants that require an allogenic peripheral blood stem cell transplant. The purpose of this study is to compare 2 combinations of drugs to prevent graft-versus-host disease (GVHD), a serious complication of a stem cell transplant. These combinations are either Tacrolimus/methotrexate or Tacrolimus/mycophenolate mofetil/cyclophosphamide. Doctors want to know which combination is better or if they give the same results. The study will help doctors decide which treatment is best at preventing GVHD for future transplant patients. Participants can expect to be in this study for up to 2 years after transplant.
This study is for patients that have been diagnosed with smoldering multiple myeloma (SMM). The drugs used in this study are daratumumab, lenalidomide and dexamethasone which are all commercially used drugs. The purpose of this study is to compare overall survival in patients with high-risk smoldering multiple myeloma randomized to daratumumab revlimid-dexamethasone or revlimid-dexamethasone. Participants can expect to be on this study for up to two years and followed by your doctor for up to 15 years.
This study is for patients that have been diagnosed with amyloid light chain (AL) amyloidosis. The Investigational drug in this study is isatuximab. The purpose of this research is to assess the efficacy as measured by the confirmed overall hematologic response rate (partial response or better) of isatuximab in relapsed/ refractory systemic light chain (AL) amyloidosis. Participants can expect to be on this study for up to 2 years and followed for up to 2 additional years after study drug completion.